MediWound Ltd. (NASDAQ:MDWD) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of MediWound Ltd. (NASDAQ:MDWD) have been given an average recommendation of “Moderate Buy” by the six research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $33.50.

Several research firms have commented on MDWD. Wall Street Zen raised MediWound from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. HC Wainwright restated a “buy” rating and issued a $36.00 target price (up from $31.00) on shares of MediWound in a research note on Friday, November 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a research report on Wednesday, October 8th. Finally, Zacks Research upgraded shares of MediWound from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th.

MediWound Price Performance

NASDAQ MDWD opened at $16.25 on Friday. The company’s fifty day moving average is $18.23 and its two-hundred day moving average is $18.32. MediWound has a 52-week low of $14.14 and a 52-week high of $22.50. The firm has a market capitalization of $180.21 million, a price-to-earnings ratio of -8.55 and a beta of 0.07.

MediWound (NASDAQ:MDWD) last released its earnings results on Thursday, November 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.57. MediWound had a negative net margin of 98.43% and a negative return on equity of 62.11%. The business had revenue of $5.43 million during the quarter, compared to analysts’ expectations of $6.56 million. As a group, sell-side analysts expect that MediWound will post -2.66 earnings per share for the current fiscal year.

Institutional Trading of MediWound

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MDWD. Rhumbline Advisers raised its position in MediWound by 4.4% in the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 481 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 649 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 723 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 999 shares in the last quarter. Finally, ARK Investment Management LLC raised its holdings in shares of MediWound by 2.3% in the 3rd quarter. ARK Investment Management LLC now owns 96,879 shares of the biopharmaceutical company’s stock worth $1,746,000 after buying an additional 2,209 shares in the last quarter. Institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.